YIDU TECH (02158) surged over 14% in late trading, and as of press time, the stock was up 12.89% to HK$6.57 with a trading volume of HK$466 million. On the news front, YIDU TECH recently announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. has won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drops Phase III clinical research project, with a total project value of approximately RMB 55.82 million. Notably, on September 16, the 2025 Tencent Digital Ecosystem Conference Medical Special Session was held. YIDU TECH's senior solution expert Shi Cheng delivered a keynote speech on "AI Empowering the Full Process of Clinical Trials," combining YIDU TECH's years of technological accumulation and practical cases to comprehensively explain the pathways through which AI can effectively improve the efficiency and quality of clinical trials from technical support and scenario implementation to ecosystem construction, driving high-quality industry development.